Altus, Genentech end ALTU-238 deal

DNA returned rights to ALTU-238 to ALTU. DNA said that the companies disagreed on the development plan for the subcutaneous long-acting formulation of somatropin recombinant human growth hormone, for which DNA had North American development and commercialization rights under a 2006 deal. An exclusive option for DNA to develop and commercialize ALTU-238 outside of North America also has expired. ALTU said it plans to resume clinical testing of ALTU-238, which had been slated to enter Phase III trials to treat growth hormone deficiency this year, by mid-2008. ...